Free Trial
OTCMKTS:BGMD

BG Medicine (BGMD) Stock Price, News & Analysis

BG Medicine logo

About BG Medicine Stock (OTCMKTS:BGMD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
250 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive BGMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BG Medicine and its competitors with MarketBeat's FREE daily newsletter.

BGMD Stock News Headlines

BG Medicine, Inc. (BGMD)
Make 22x more from this summer’s Bitcoin boom
Bitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors are finally starting to believe. But here’s the twist: Some of the biggest profits aren’t going to the people who hold Bitcoin. They’re going to those who “skim” it. Bitcoin Skimming has already CRUSHED Bitcoin’s returns.
Modernizing Medicine
Medicine Through Time
BGMD - BG Medicine, Inc.
Jiangsu Hengrui Medicine
See More Headlines

BGMD Stock Analysis - Frequently Asked Questions

BG Medicine Inc. (OTCMKTS:BGMD) posted its quarterly earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) earnings per share for the quarter. The medical research company had revenue of $334 million for the quarter, compared to analyst estimates of $695 million.

Shares of BGMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BG Medicine investors own include Aeterna Zentaris (AEZS), Glu Mobile (GLUU), Blue Ridge Mountain Resources (MHRCQ), ARCA biopharma (ABIO), Athersys (ATHX), Bristol Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/17/2015
Today
6/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Medical Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
OTCMKTS:BGMD
Previous Symbol
NASDAQ:BGMD
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
2.58
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:BGMD) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners